Edesa Biotech, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q4 2025.
-
Symbol
-
EDSA on Nasdaq
-
Location
-
Markham
-
Fiscal year end
-
30 September
-
Latest financial report
-
13 Feb 2026
Quick Takeaways
- EDSA - Edesa Biotech, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity -96%.
What Changed
- Return On Equity YoY change: <span class="text-red-600">-36%</span>.
- Most recent SEC facts end date: 31 Dec 2025.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2025-12-31) highlights Return On Equity -96.4%, Return On Assets -55.3%, and Operating Margin 0.0%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
3.6/100
Weak
Confidence medium
Return On Equity
-96%
Metric score 0.0/100
Return On Assets
-55%
Metric score 0.0/100
Financial Health
- Current Ratio
- 16.82x
- Quick Ratio
- 16.51x
Strengths
No strong signals yet.
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
-96%
YoY: -36%
Industry median:
-43%
(n=671)
View history
Return On Assets
-55%
YoY: -19%
Industry median:
-48%
(n=669)
View history
Operating Margin
0%
YoY:
Industry median:
-128%
(n=298)
View history
Current Ratio
16.82x
YoY: +1442%
Industry median:
3.39x
(n=667)
View history
Quick Ratio
16.51x
YoY:
Industry median:
2.02x
(n=287)
View history
NetIncomeLoss YoY
-28%
YoY:
Industry median:
-0.54%
(n=641)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
-96%
|
-36%
|
-43%
(n=671)
|
Q4 2025
|
Q1 2026
|
%
|
|
Return On Assets
|
-55%
|
-19%
|
-48%
(n=669)
|
Q4 2025
|
Q1 2026
|
%
|
|
Operating Margin
|
0%
|
|
-128%
(n=298)
|
Q4 2025
|
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
16.82x
|
+1442%
|
3.39x
(n=667)
|
Q4 2025
|
Q1 2026
|
x
|
|
Quick Ratio
|
16.51x
|
|
2.02x
(n=287)
|
Q4 2025
|
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
NetIncomeLoss YoY
|
-28%
|
|
-0.54%
(n=641)
|
Q4 2025
|
Q1 2026
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
8,333,823
|
+140%
|
Q4 2025
|
FY 2025
|
shares
|
|
Common Stock, Shares, Outstanding
|
8,333,823
|
+140%
|
Q4 2025
|
Q1 2026
|
shares
|
|
Common Stock, Value, Issued
|
$57,899,593
|
+22%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
7,972,532
|
+138%
|
Q4 2025
|
Q1 2026
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Research and Development Expense
|
$3,773,647
|
+18%
|
Q4 2025
|
Q1 2026
|
USD
|
|
General and Administrative Expense
|
$4,580,613
|
+19%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Operating Income (Loss)
|
$8,354,260
|
-18%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Nonoperating Income (Expense)
|
$539,121
|
-43%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Earnings Per Share, Basic
|
-1.07
|
+43%
|
Q4 2025
|
Q1 2026
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$12,100,000
|
+656%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Assets, Current
|
$12,717,487
|
+514%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Assets
|
$14,710,442
|
+253%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Liabilities, Current
|
$756,163
|
-60%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$171,086
|
+24%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$68,196,040
|
-13%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$13,954,279
|
+516%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Liabilities and Equity
|
$14,710,442
|
+253%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Share-based Payment Arrangement, Noncash Expense
|
$399,862
|
+393%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Net Cash Provided by (Used in) Operating Activities
|
$2,087,334
|
-38%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Net Cash Provided by (Used in) Financing Activities
|
$3,355,419
|
+62%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Common Stock, Shares, Issued
|
8,333,823
|
+140%
|
Q4 2025
|
Q1 2026
|
shares
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
|
$1,259,576
|
+139%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$12,051,748
|
+671%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$7,763,068
|
-27%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Additional Paid in Capital
|
$15,124,219
|
+6.7%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Amortization of Intangible Assets
|
$30,000
|
0%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Depreciation, Depletion and Amortization
|
$25,460
|
-41%
|
Q4 2025
|
Q1 2026
|
USD
|
|
Share-based Payment Arrangement, Expense
|
$400,000
|
+400%
|
Q4 2025
|
Q1 2026
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets